期刊
CELLS
卷 9, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/cells9040924
关键词
SARS-CoV-2; COVID-19; acute respiratory distress syndrome; mesenchymal stem cells; extracellular vesicles; microvesicles; exosomes; secretome
类别
资金
- Interreg V-A Italy-Switzerland 2014-2020-ATEx-Advanced Therapies Experiences [637541]
From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据